GSK is scheduled to report results for the first quarter on Wednesday. Here is what to know. SALES FORECAST: The British pharmaceutical giant is expected to report sales for the period of 7.42 ...

We aim to explore its current performance. Present Market Standing of GSK With a volume of 19,701,072, the price of GSK is up 5.97% at $40.29.

GSK GSK 0.99 % increase; green up pointing triangle plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

This article was corrected at 0907 GMT to reflect GSK's core earnings per share fell 10% at constant currencies to 23.2 pence, above analysts' expectations of 20.6 pence.

In its Q3 results, GSK , the first to receive U.S. approval for an RSV vaccine in May 2023, said its Arexvy vaccine added £188M in sales, indicating ~ a 73% YoY drop.

Moderna’s (MRNA) Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is shrinking. Read more here.

And GSK’s first-to-market Arexvy lived up to that expectation with $1.5 billion sales in its first year of commercialization. Related As RSV vaccine clash kicks off, GSK sues Pfizer for patent ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed ... GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why.

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £13.50. The company’s shares ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

British drugmaker GlaxoSmithKline will seek marketing approval for the world's first malaria vaccine next year ... data and analytics for financial market professionals Learn more about Refinitiv.